Description
Objectifs d'apprentissage
LES PLACES SONT LIMITÉES
À la fin de cette conférence, les participants seront en mesure de:
Implementing the new 2021 Canadian lipid guidelines
1. Cite and implement the new 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult;
2. Learn the utility of using nHDL or Apo B in guiding decision manking especially at low levels of LDL;
3. Cite the evidence for CAC to improve risk assessment and the risk benefit analysis considering incidentalomas discovered on CAC scans. Define which type of patient should be screened with CAC;
4. Cite the evidence for the use of carotid doppler to improve risk assessment;
5. Cite the evidence for icosapent ethyl to lower the risk of cardiovascular events and how to implement this clinically;
6. Define the role of PCSK9 to lower the risk of cardiovascular events in both primary and secondary prevention.
Osteoporosis in real practice: Answers to common clinical questions
1. Identify indications for treating osteoporosis especially in patients with a normal bone density as measured by the T score and quantify the benefits of treatment including the NNT for osteoporosis in primary and secondary prevention for vertebral, non vertebral and hip fractures amongst the various pharmacotherapies;
2. Define treatment duration amongst the various patient risk groups, and in those with fragility fractures how the site of fragility fracture might influence treatment duration;
3. Define the role of bone turnover markers (and useful reference ranges) and identify criteria indicating treatment failure and the causes thereof while developing clinical approaches to intervene;
4. Identify patients treated with bisphospohates in whom drug holidays are appropriate and elaborate strategies on how to monitor and reassess these patients over time;
5. Identify patients who are candidates for anabolic agents and define the role of the choices of molecules available and how to choose one over the other;
6. Define treatment duration for denosumab and if stopped for a clinical reason, define strategies of sequential therapy. Define sequential therapy following discontinuation of and the anabolic agents, PTH analog and anti sclerostin inhibitor, and how to reassess over time.
5. Évaluer le positionnement d’un traitement biologique comme options thérapeutiques.
Conférenciers
Président de séance : Dr Jonathan Singerman. Conférences données par les Drs Morris Schweitzer et Peter Assimakopoulos.
Horaire
De 18 h 30 à 18 h 35, Accueil
De 18 h 35 à 20 h 05, Conférence
De 20 h 05 à 20 h 10, Pause
De 20 h 10 à 21 h 40, Conférence
Questions
Pour toutes questions, SVP communiquer avec Nadine Grunberg d'Amgen Canada au 514 515-3752 ou à ngrunber@amgen.com.
Reconnaissance des activités éducatives
L’Association des médecins omnipraticiens de Montréal, sous l’agrément parapluie de la FMOQ, reconnaît 3.00 heures de crédits de catégorie 1 aux participants à cette activité. Numéro FMOQ pour récupérer votre attestation : 78551.
Formation subventionnée
Cette activité bénéficie d’une subvention à visée éducative d'Amgen Canada.
